Examples of 'ramucirumab' in a sentence
Meaning of "ramucirumab"
Ramucirumab is an adjective used in medical terminology, specifically in reference to a type of drug
Show more definitions
- A monoclonal antibody used in the treatment of solid tumours.
How to use "ramucirumab" in a sentence
Basic
Advanced
ramucirumab
The metabolism of ramucirumab has not been studied.
Ramucirumab inhibited angiogenesis in an in vivo animal model.
It is unknown whether ramucirumab is excreted in human milk.
Cyramza contains the active substance ramucirumab.
Ramucirumab therapy should be permanently discontinued in the event of.
No patients had neutralising antibodies to ramucirumab.
Ramucirumab in combination with docetaxel.
There are no data on the effect of ramucirumab on human fertility.
Ramucirumab in combination with paclitaxel.
The active substance is ramucirumab.
Ramucirumab as a single agent.
Posology adjustments for ramucirumab.
Ramucirumab therapy must be initiated and supervised by physicians experienced in oncology.
There are no data from the use of ramucirumab in pregnant women.
Ramucirumab therapy should be permanently discontinued if the urine protein level is.
See also
Aseptically transfer the calculated volume of ramucirumab to the intravenous container.
Cases of gastrointestinal perforation have been reported in patients treated with ramucirumab.
No animal studies have been performed to test ramucirumab for potential of carcinogenicity or genotoxicity.
Ramucirumab is an antiangiogenic therapy and may increase the risk of gastrointestinal perforations.
An increased incidence of proteinuria was reported in patients receiving ramucirumab as compared to placebo.
Ramucirumab is an antiangiogenic therapy and may increase the risk of severe bleeding.
The majority of events occurred during or following a first or second ramucirumab infusion.
Aseptically transfer the calculated volume of ramucirumab into an empty intravenous infusion container.
Patients should be monitored for the development or worsening of proteinuria during ramucirumab therapy.
Patients who are treated with ramucirumab should have their blood pressure monitored.
You may need to monitor your blood pressure at home while taking ramucirumab.
Calculate the dose and volume of ramucirumab needed to prepare the infusion solution.
Ramucirumab should be temporarily discontinued for severe hypertension until controlled with medical management.
Was an improvement in survival with the addition of Ramucirumab for overall survival.
Docetaxel or docetaxel plus ramucirumab for patients who had severe side effects from immunotherapy.
Infusion-related reactions were reported in clinical studies with ramucirumab.
This is the first regulatory action for ramucirumab in Europe in any indication.
Ramucirumab in combination with FOLFIRI.
In a study conducted in animals, ramucirumab did not impair wound healing.
The pharmacokinetics of docetaxel were not affected when co-administered with ramucirumab.
Ramucirumab therapy should be temporarily discontinued for at least 4 weeks prior to elective surgery.
No drug-drug interactions were observed between ramucirumab and paclitaxel.
The impact of ramucirumab has not been evaluated in patients with serious or non-healing wounds.
Exposure-response analyses indicated that efficacy was correlated with ramucirumab exposure across pivotal studies.
A single dose of ramucirumab did not impair wound healing in monkeys using a full-thickness incisional model.
Premedication is recommended with a histamine H1 antagonist ( for example diphenhydramine ) prior to infusion of ramucirumab.
The recommended dose of ramucirumab as a single agent is 8 mg / kg every 2 weeks.
Cyramza 10 mg / ml concentrate for solution for infusion ramucirumab.
Ramucirumab treatment should be discontinued in patients who develop fistula see section 4.2.
One ml of concentrate for solution for infusion contains 10 mg ramucirumab.
Ramucirumab should be permanently discontinued in patients who experience gastrointestinal perforations see section 4.2.
One ml of concentrate contains 10 mg ramucirumab.
Ramucirumab is a fully human monoclonal antibody ( IgG1 ) developed for the treatment of solid tumors.
In RAISE, the incidence of Grade ≥ 3 neutropenia was increased with higher ramucirumab exposure.
Table 3, Ramucirumab dose reductions for proteinuria.
